Chemistry:Lorundrostat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | MLS 101 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H33N7O2 |
| Molar mass | 451.575 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants.[1][2][3][4]
References
- ↑ Laffin, Luke J.; Rodman, David; Luther, James M.; Vaidya, Anand; Weir, Matthew R.; Rajicic, Natasa; Slingsby, B. T.; Nissen, Steven E. et al. (26 September 2023). "Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial" (in en). JAMA 330 (12): 1140–1150. doi:10.1001/jama.2023.16029. ISSN 0098-7484. PMID 37690061.
- ↑ Rodman, David; Weir, Matthew R.; Slingsby, Bt; Laffin, Luke; Nissen, Steven E. (March 2023). "Highly Effective Blood Pressure Lowering with MLS-101, A New Aldosterone Synthase Inhibitor, in Individuals with Obesity and Raas Dysregulation" (in en). Journal of the American College of Cardiology 81 (8): 306. doi:10.1016/S0735-1097(23)00750-7. https://www.jacc.org/doi/full/10.1016/S0735-1097%2823%2900750-7.
- ↑ Fujii, Aya; Hiraga, Yuki; Kawai, Mizue; Ogawa, Kei; Ohta, Yoshiyasu; Rahman, Sheikh Mohammed Ashfaq; Shimizu, Hidetoshi; Sugimoto-Kawabata, Kanami et al. (March 2023). "First-In-Human Study of MLS-101, A Potent and Highly Selective Aldosterone Synthase Inhibitor" (in en). Journal of the American College of Cardiology 81 (8): 616. doi:10.1016/S0735-1097(23)01060-4. https://www.jacc.org/doi/full/10.1016/S0735-1097%2823%2901060-4.
- ↑ Irfan, Hamza; Ahmed, Aliza; Nawani, Komal Devi (January 2024). "Hypertension and Lorundrostat: Key Discoveries From the TARGET-HTN Trial". Current Problems in Cardiology 49 (1): 102144. doi:10.1016/j.cpcardiol.2023.102144. PMID 37858848.
 |  |
